PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer

British Journal of Cancer

Volumn 102, Issue 2, 2010, Pages 361-368

  Munkacsy G ^a   Abdul Ghani, R ^b   Mihaly Z ^a   Tegze, B ^a   Tchernitsa, O ^c   Surowiak, P ^c,d   Schafer R ^c   Gyorffy B ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b AL QUDS UNIVERSITY   (Palestine)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Biomarker; Breast cancer; Doxorubicin; Gene expression; PSMB7; RNA interference

Indexed keywords

DOXORUBICIN; ONCOPROTEIN; PACLITAXEL; PROTEASOME UNIT BETA TYPE 7; UNCLASSIFIED DRUG;

ARTICLE; AUTOFLUORESCENCE; BREAST CANCER; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RNA INTERFERENCE;

ANTHRACYCLINES; BREAST NEOPLASMS; CYSTEINE ENDOPEPTIDASES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 75549086500     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605478     Document Type: Article

References (53)

1. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622
2. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L (2007) Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 13: 2061-2067
3. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22: 2284-2293 (Pubitemid 41115384)
4. Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A (2008) The addition of liposomal doxorubicin to bortezomib, thalidomide and dexametha-sone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 141: 814-819
5. Clark MS, Shaw L, Kelly A, Snell P, Elgar G (2001) Characterization of the MHC class I region of the Japanese pufferfish (Fugu rubripes). Immunogenetics 52: 174-185
6. Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM, Dickson RB (1992) Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst 84: 1506-1512
7. Cleator SJ, Powles TJ, Dexter T, Fulford L, Mackay A, Smith IE, Valgeirsson H, Ashworth A, Dowsett M (2006) The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res 8: R32
8. Folgueira MAAK, Carraro DM, Brentani H, Patra DFD, Barbosa EM, Netto MM, Caldeira JRF, Katayama MLH, Soares FA, Oliveira CT, Reis LFL, Kaiano JHL, Camargo LP, Vencio RZN, Snitcovsky IML, Makdissi FBA, Silva PJDE, Goes JCGS, Brentani MM (2005) Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11: 7434-7443
9. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741
10. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23: 7265-7277
11. Gil MA, Sherwood KE, Maupin-Furlow JA (2007) Transcriptional linkage of Haloferax volcanii proteasomal genes with non-proteasomal gene neighbours including RNase P, MOSC domain and SAM-methyltransfer-ase homologues. Microbiology 153: 3009-3022
12. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58
13. Gyorffy B, Serra V, Jurchott K, bdul-Ghani R, Garber M, Stein U, Petersen I, Lage H, Dietel M, Schafer R (2005) Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 24: 7542-7551
14. Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, Dietel M, Lage H (2006) Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699-1712
15. Gyorffy B, Schafer R (2009) Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res Treat 118: 433-441
16. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast Jr RC (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312 (Pubitemid 350232263)
17. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24: 4236-4244
18. Hoffman EP, Awad T, Palma J, Webster T, Hubbell E, Warrington JA, Spirais A, Wright G, Buckley J, Triche T, Davis R, Tibshirani R, Xiao WH, Jones W, Tompkins R, West M (2004) Guidelines-expression profiling-best practices for data generation and interpretation in clinical trials. Nat Rev Genet 5: 229-237
19. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15
20. Kamata S, Kishimoto T, Kobayashi S, Miyazaki M (2008) Expression and localization of ATP binding cassette (ABC) family of drug transporters in gastric hepatoid adenocarcinomas. Histopathology 52: 747-754
21. Kane RC, Farrell AT, Sridhara R, Pazdur R (2006) United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12: 2955-2960
22. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo BC, Kim HK, Park JG (2004) Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10: 272-284
23. Karukstis KK, Thompson EH, Whiles JA, Rosenfeld RJ (1998) Deciphering the fluorescence signature of daunomycin and doxorubicin. Biophys Chem 73: 249-263
24. Kwak MK, Huang B, Chang H, Kim JA, Kensler TW (2007a) Tissue specific increase of the catalytic subunits of the 26S proteasome by indirect antioxidant dithiolethione in mice: enhanced activity for degradation of abnormal protein. Life Sci 80: 2411-2420
25. Kwak MK, Huang B, Chang H, Kim JA, Kensler TW (2007b) Tissue specific increase of the catalytic subunits of the 26S proteasome by indirect antioxidant dithiolethione in mice: enhanced activity for degradation of abnormal protein. Life Sci 80: 2411-2420
26. Lage H, Dietel M (2002) Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. Cancer Res Clin Oncol 128: 349-357
27. Larbcharoensub N, Leopairat J, Sirachainan E, Narkwong L, Bhongmakapat T, Rasmeepaisarn K, Janvilisri T (2008) Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy. Hum Pathol 39: 837-845
28. Ludwig H, Khayat D, Giaccone G, Facon T (2005) Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104: 1794-1807
29. Mano MS, Rosa DD, De AE, Ismael GF, Durbecq V (2007) The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat Rev 33: 64-77
30. Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E (2003) Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclopho-sphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 14: 833-842
31. Michalova V, Murray BW, Sultmann H, Klein J (2000) A contig map of the Mhc class I genomic region in the zebrafish reveals ancient synteny. J Immunol 164: 5296-5305
32. Molina R, Barak V, van DA, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Soletormos G, Stieber P (2005) Tumor markers in breast cancer-European Group on Tumor Markers recommendations. Tumour Biol 26: 281-293 (Pubitemid 41619458)
33. Montagut C, Rovira A, Mellado B, Gascon P, Ross JS, Albanell J (2005) Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment. Drugs Today (Barc) 41: 299-315
34. Montagut C, Rovira A, Albanell J (2006) The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 8: 313-317
35. Murata S, Sasaki K, Kishimoto T, Niwa S, Hayashi H, Takahama Y, Tanaka K (2007) Regulation of CD8+ T cell development by thymus-specific proteasomes. Science 316: 1349-1353
36. Nguyen T, Menocal EM, Harborth J, Fruehauf JH (2008) RNAi therapeutics: an update on delivery. Curr Opin Mol Ther 10: 158-167
37. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van ZI, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112: 2489-2499
38. Rho JH, Qin S, Wang JY, Roehrl MH (2008) Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J Proteome Res 7: 2959-2972
39. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102: 8315-8320
40. Sabourin M, Osheroff N (2000) Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Res 28: 1947-1954
41. Schewe DM, guirre-Ghiso JA (2009) Inhibition of eIF2alpha depho-sphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res 69: 1545-1552
42. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K (2008) Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S- transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest 26: 344-351
43. Shi XH, Liang ZY, Ren XY, Liu TH (2009) Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther 16: 227-236
44. Sterz J, von MI, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O (2008) The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 17: 879-895
45. Sturn A, Quackenbush J, Trajanoski Z (2002) Genesis: cluster analysis of microarray data. Bioinformatics 18: 207-208
46. Surowiak P, Paluchowski P, Dziegiel P, Wysocka T, Wojnar A, Spaczynski M, Zabel M (2004) Lack of relationship between metallothionein (MT) expression and proliferation exponents in cells of primary ductal breast cancer of G2 grade of differentiation. Med Sci Monit 10: BR300-BR305
47. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, Wilking N, Nilsson J, Bergh J (2006) Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24: 2428-2436
48. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99: 6567-6572
49. Xiao H, Wu Z, Shen H, Luo AL, Yang YF, Li XB, Zhu DY (2008) In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi. Basic Clin Pharmacol Toxicol 103: 342-348
50. Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu TF, Xie WB, Yao KT (2008) Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med 6: 55
51. Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J, Tian Z (2008) Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 14: 6432-6439
52. Zhang X, Ge YL, Tian RH (2009) The knockdown of c-myc expression by RNAi inhibits cell proliferation in human colon cancer HT-29 cells in vitro and in vivo. Cell Mol Biol Lett 14: 305-318
53. Zhou G, Kowalczyk D, Humbard MA, Rohatgi S, Maupin-Furlow JA (2008) Proteasomal components required for cell growth and stress responses in the haloarchaeon Haloferax volcanii. J Bacteriol 190: 8096-8105